These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 23221494

  • 1. Medical treatment of neuroendocrine tumours.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [Abstract] [Full Text] [Related]

  • 2. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R, Meyer T.
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [Abstract] [Full Text] [Related]

  • 3. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 4. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA, Kim M, Wenger SD, O'Bryant CL.
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [Abstract] [Full Text] [Related]

  • 5. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 6. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK, Bergsland EK.
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [Abstract] [Full Text] [Related]

  • 7. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G.
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [Abstract] [Full Text] [Related]

  • 8. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [Abstract] [Full Text] [Related]

  • 9. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J, Argilés G, Mulet-Margalef N, Tabernero J.
    Endocrinol Nutr; 2012 Mar; 59(7):438-51. PubMed ID: 22565119
    [Abstract] [Full Text] [Related]

  • 10. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A, Bhatt V.
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [Abstract] [Full Text] [Related]

  • 11. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S, Sablin MP, Dreyer C, Raymond E.
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A, Bodoky G.
    Orv Hetil; 2011 Mar 06; 152(10):379-91. PubMed ID: 21354954
    [Abstract] [Full Text] [Related]

  • 13. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S, Saif MW.
    Curr Opin Oncol; 2015 Jan 06; 27(1):38-43. PubMed ID: 25390554
    [Abstract] [Full Text] [Related]

  • 14. Recent studies show promise for treating rare pancreatic tumors.
    Peres J.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):624-7. PubMed ID: 21474831
    [No Abstract] [Full Text] [Related]

  • 15. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K.
    Curr Opin Oncol; 2012 Jul 20; 24(4):433-40. PubMed ID: 22510940
    [Abstract] [Full Text] [Related]

  • 16. Advances in the treatment of pancreatic neuroendocrine tumours.
    Gao F, Visvardis EE, Sita-Lumsden A, Waxman J.
    QJM; 2012 Sep 20; 105(9):819-22. PubMed ID: 22383691
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C.
    Neuroendocrinology; 2013 Sep 20; 97(4):331-40. PubMed ID: 23343749
    [Abstract] [Full Text] [Related]

  • 18. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG, Strosberg JR, Halfdanarson TR.
    Oncology; 2012 Sep 20; 83(3):117-27. PubMed ID: 22797357
    [Abstract] [Full Text] [Related]

  • 19. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.
    Expert Opin Pharmacother; 2012 Oct 20; 13(14):2073-84. PubMed ID: 22873789
    [Abstract] [Full Text] [Related]

  • 20. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP.
    Gastroenterology; 2010 Sep 20; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.